Klotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy Assets

Rhea-AI Summary

Klotho Neurosciences (NASDAQ: KLTO) has announced a strategic partnership with AAVnerGene Inc. to manufacture its gene therapy candidates using AAVnerGene's advanced AAV manufacturing and tissue-targeted delivery technologies.

The collaboration aims to accelerate the development of KLTO's three key candidates: KLTO-101 for Alzheimer's and Parkinson's diseases, KLTO-202 for ALS and motor neuron diseases, and KLTO-303 for aging-related pathologies. AAVnerGene's proprietary platforms - AAVone system and ATHENA platform - promise to deliver more cost-effective, faster manufacturing with higher efficacy, purity, and lower toxicity through improved tissue targeting.

Positive

• None.

Negative

• No immediate revenue generation from early-stage partnership
• Success depends on unproven manufacturing technology integration

News Market Reaction

+12.50%

15 alerts

+12.50% News Effect

+27.2% Peak in 18 hr 49 min

+$8M Valuation Impact

$71M Market Cap

0.2x Rel. Volume

On the day this news was published, KLTO gained 12.50%, reflecting a significant positive market reaction. Argus tracked a peak move of +27.2% during that session. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $8M to the company's valuation, bringing the market cap to $71M at that time.

Data tracked by StockTitan Argus on the day of publication.

NEW YORK, July 22, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), announced that it is partnering with AAVnerGene Inc. (AAVnerGene), a Rockville, MD-based innovation-driven biotech renowned for its transformative technologies in AAV manufacturing and tissue-targeted delivery. 

Dr. Joseph Sinkule, the CEO of KLTO stated "we announced previously that we have been looking for a more efficient, 'next-generation' method to manufacture several of our patented gene therapy candidates, and the two platform technologies offered by AAVnerGene will catapult our product candidates into the clinic at a faster pace, at a lower cost, a higher efficacy and purity compared to the current state-of-the-art AAV manufacturing processes. We are talking about KLTO-101 for Alzheimer's and Parkinson's diseases, KLTO-202 for ALS and other motor neuron diseases, and KLTO-303 for treatment of ageing-related pathologies resulting in a healthy, extended lifespan. I'm also looking at other complementary longevity-related assets that we may bring into KLTO."

"AAV gene therapy has been proven to be a revolutionary one-time, life-changing treatment, however it is experiencing some crisis caused by high drug price and high dose-related toxicity," said Dr. Daozhan Yu, Founder and CEO of AAVnerGene. "We envisioned these bottleneck problems six years ago and AAVnerGene was founded with the mission to solve them. With the two proprietary platforms, we can dramatically drive down the manufacture cost with the AAVone system and the dose required by the highly efficient and specific tissue-targeting AAVs developed with the ATHENA platform. It's a perfect synergy to partner with Klotho, a neuroscience-driven pathfinder.   Neurological disease drug development is always challenging and we need new approaches and mechanisms. Klotho's data on neuron protection and longevity are very impressive and it holds the potential to treat so many devastating diseases. We are very glad to work with the passionate and highly executive team, and strongly believe that the collaboration can bring more affordable and innovative drugs for patients with rare and common diseases."

Dr. Joseph Sinkule concluded "Klotho believes AAVnerGene has conceived a process method that is more cost effective, faster to make, has fewer impurities, shows higher efficacy and lower toxicity because of the higher targeted tissue delivery.  KLTO hopes to work with AAVnerGene for manufacturing several of our product candidates composed of a tissue-specific promoter driving our Klotho gene to produce the Klotho protein and elevated concentrations of the protein in specific, targeted tissues and organs affected by these neurologic and neuromuscular diseases."

About AAVnerGene, Inc. AAVnerGene is a creativity-powered biotechnology company pioneering next-generation AAV vector technologies. The company's proprietary platforms include AAVone, a high-yield, single-plasmid AAV production system that dramatically reduces manufacturing costs, and ATHENA, an advanced capsid engineering platform enabling precise tissue targeting. AAVnerGene is dedicated to delivering affordable, scalable, and precision-engineered gene therapy solutions that accelerate clinical development across diverse therapeutic areas.

Investor Contact and Corporate Communications – Daozhan Yu, CEO
daozhan.yu@aavnergene.com
Website: www.aavnergene.com

About Klotho Neurosciences, Inc. Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and it's novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.

Investor Contact and Corporate Communications - Jeffrey LeBlanc, CFO
ir@klothoneuro.com

Website: www.klothoneuro.com

Forward-Looking Statements:

This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company's future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company's inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements.  All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/klotho-neurosciences-inc-partners-with-aavnergene-inc-to-make-klothos-gene-therapy-assets-302510843.html

SOURCE Klotho Neurosciences, Inc.

FAQ

What is the partnership between Klotho Neurosciences (KLTO) and AAVnerGene?

KLTO has partnered with AAVnerGene to manufacture its gene therapy candidates using AAVnerGene's advanced AAV manufacturing and tissue-targeted delivery technologies, aiming for more efficient and cost-effective production.

What are the main drug candidates that KLTO is developing?

KLTO is developing KLTO-101 for Alzheimer's and Parkinson's, KLTO-202 for ALS and motor neuron diseases, and KLTO-303 for aging-related pathologies.

How will AAVnerGene's technology benefit KLTO's gene therapy production?

AAVnerGene's technology promises to provide faster manufacturing, lower costs, higher efficacy, better purity, and reduced toxicity compared to current AAV manufacturing processes.

What are the key platforms that AAVnerGene brings to the partnership?

AAVnerGene brings two key platforms: the AAVone system for cost-effective manufacturing and the ATHENA platform for highly efficient and specific tissue-targeting AAVs.

What therapeutic areas will benefit from the KLTO-AAVnerGene partnership?

The partnership will focus on developing treatments for neurological and neuromuscular diseases, including Alzheimer's, Parkinson's, ALS, and aging-related pathologies.